The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1(G93A) and TDP-43(Q331K) transgenic mouse models of ALS

GLP-1 receptor agonists used for the treatment of diabetes, have shown some neuroprotective effects in cellular and animal models of Alzheimer’s disease (AD) and Parkinson’s disease (PD). There are currently few studies investigating GLP-1 receptor agonists in the treatment of ALS, where these neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Keerie, Amy, Brown-Wright, Heledd, Kirkland, Isaac, Grierson, Andrew, Alix, James J. P., Holscher, Christian, Mead, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382676/
https://www.ncbi.nlm.nih.gov/pubmed/34426623
http://dx.doi.org/10.1038/s41598-021-96418-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382676/
https://www.ncbi.nlm.nih.gov/pubmed/34426623
http://dx.doi.org/10.1038/s41598-021-96418-0

Ejemplares similares